Table 3. Factors associated with mortality at 28-days of follow up and the requirement of kidney replacement therapy in hospitalized COVID patients, in the univariable and multivariable logistic regression model.
| Univariable analysis, OR (95% CI) | p | Multivariable analysis, OR (95% CI) | p | |
|---|---|---|---|---|
| Mortality | ||||
| Age > 60 [years] | 1.20 (1.13–1.27) | <0.001 | 1.12 (1.06–1.18) | <0.001 |
| COVID severity | ||||
| Mild | Reference | - | Reference | - |
| Severe | 1.41 (1.33–1.49) | <0.001 | 1.09 (1.03–1.16) | 0.002 |
| Need in mechanical lung ventilation | 1.82 (1.72–1.93) | <0.001 | 1.67 (1.56–1.78) | <0.001 |
| AKI acquisition and KDIGO stage | ||||
| CA-AKI and stage 2–3 | Reference | - | Reference | - |
| HA-AKI and stage 2 | 1.38 (1.18–1.63) | <0.001 | 1.11 (0.97–1.27) | 0.10 |
| HA-AKI and stage 3 | 1.43 (1.27–1.61) | <0.001 | 1.16 (1.05–1.29) | 0.003 |
| Kidney replacement therapy | ||||
| CKD | 1.69 (1.59–1.78) | <0.001 | 1.48 (1.391.56) | <0.001 |
| Serum Lymphocytes < 1000 [μL] | 1.10 (1.06–1.15) | <0.001 | 1.03 (1.00–1.07) | 0.03 |
| Need in mechanical lung ventilation | 1.12 (1.07–1.18) | <0.001 | 1.06 (1.02–1.11) | 0.003 |
| AKI acquisition and KDIGO stage | ||||
| HA-AKI and stage 2–3 | Reference | - | Reference | - |
| CA-AKI and stage 2 | 0.99 (0.90–1.08) | 0.90 | ||
| CA-AKI and stage 3 | 1.66 (1.56–1.76) | <0.001 | 1.37 (1.29–1.46) | <0.001 |
AKI, acute kidney injury; CA-AKI, community-acquired AKI; HA-AKI, hospital-acquired AKI; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; KRT, kidney replacement therapy.